Researchers have found a link between low testosterone levels and aggressive tumors, which could change how prostate cancer ...

Amanda Peet detailed her recent breast cancer diagnosis in a new essay, sharing that her health battle coincided with both of ...

Joe Biden's battle with stage 4 metastatic prostate cancer has raised new questions about when his illness began, after a ...

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

Hampshire Hospitals NHS Foundation Trust pioneers Aquablation therapy for prostate cancer in UK clinical trial.

Pfizer PFE reported positive top-line results from a late-stage study evaluating Talzenna (talazoparib), an oral PARP inhibitor, in combination with Xtandi (enzalutamide), an ARP inhibitor. The ...

Former newspaper reporter Gary Ralston - who is undergoing his own battle with prostate cancer - took on the punishing Hyrox ...

Phase 3 TALAPRO-3 results show that talazoparib plus enzalutamide significantly improves radiographic progression-free survival in HRR-mutated metastatic castration-sensitive prostate cancer, ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

While sales of Talzenna, which Pfizer acquired in a $14 billion deal, have been “negligible” so far, the new results should ...

Pfizer Inc. (NYSE:PFE) announced that its Phase 3 TALAPRO-3 clinical trial met its primary endpoint, demonstrating that the combination of TALZENNA (talazoparib) and XTANDI (enzalutamide) ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...